4-(Methylsulfonyl) Acidum phenylaceticum CAS 90536-66-6 Puritas >99.5% (HPLC)
Ducens Fabrica et Supplier, Intermedia de Etoricoxib
Etoricoxib API CAS 202409-33-4
4-(Methylthio) Acidum Phenylaceticum CAS 16188-55-9
4-(Methylsulfonyl) Acidum Phenylaceticum CAS 90536-66-6
Please contact: alvin@ruifuchem.com
| Nomen chemicum | 4-(Methylsulfonyl) phenylaceticum acidum |
| Synonyma | 4-Methylsulphonylphenylacetic Acid;4-(Methanesulfonyl) phenylaceticum Acidum;(4-Methanesulfonylphenyl) acetic Acidum;4-Methylsulfonyl Phenyl Acidum aceticum;2-(4-(Methylsulfonyl)phenyl)acetic Acidum;[p-(Methylsulfonyl)phenyl]4-Mesylphenylacetic Acid |
| CAS Number | 90536-66-6 |
| CATTUS Number | RF-PI1182 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C9H10O4S |
| M. Pondus | 214.24 |
| Liquescens punctum | 136.0 ad 140.0℃ |
| Density | 1.35 |
| Solubilitas | Solutum in Methanol |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | White ad Off-White solidus pulveris |
| Puritas / Analysis Methodus | >99.5% (HPLC) |
| Liquescens punctum | 136.0 ad 140.0℃ |
| Humor (KF) | <0.50% |
| Uno maxima immunditia | <0.30% |
| Totalis immunditias | <0.50% |
| Infrared Imaginis | Conformat ut Structure |
| Test Standard | Enterprise Standard |
| Consuetudinem | Medium Etoricoxib (CAS: 202409-33-4) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
4-(Methylsulfonyl) Acid phenylaceticum (CAS: 90536-66-6) medium est ex Etoricoxib (CAS: 202409-33-4).Etoricoxib genus est cyclooxygenase-selectivum valde 2 (COX-2) inhibitoribus a comitatu Merck elaboratum.Etoricoxib late in curatione OSTEOARTHRITIS (OA), arthritis rheumatoideis, spondylitis ankylosing, longis retro dolor, podagris acutis, arthritis primariis dysmenorrhea et postoperative, aliisque morbis.Etoricoxib, COX-2 inhibitor selectivus, effectus habet anti-inflammatores, analgesicos et antipyreticos, aptus curationi symptomatum et signa osteoarthritis acutis et longis, item arthritis acutis podagrae.Celeriter Etoricoxib absorbetur, cum bioavailability oralis 80 ad 100%, et maximam plasma concentrationis in 1 ad 2 horas post dosing pervenit.Cibus minuit effusio ratem, sed in quantum effusio non valet.Exhibet longam eliminationem vitae dimidiae circiter 22 horarum, demonstrans plasma pharmacokineticorum linearium sine cumulatione in multiplici dosing.
